CME Internet Symposium

AIDS2020_eSymp_Banner

 

 

AIDS20_web_button

 

 

 

About the Program

Program Overview

The ARV Therapies and Therapeutic Strategies program is a comprehensive, independent review of the 23rd International AIDS Conference (AIDS 2020). This program consists of four components: (1) CME Internet Symposium: AIDS 2020 Expert Review: an Internet symposium that features an overview of key presentations and posters, selected by the expert faculty; (2) From Conference to Clinic**: Reviewing and Applying Data from AIDS 2020: a case-based on-line webcast featuring expert faculty reviewing key presentations with a focus on clinical management and treatment; (3) Rapid-Fire Review of AIDS 2020: a podcast that provides a brief, audio summary of the most essential data presented at the conference; and (4) AIDS 2020 e-Newsletter**: a brief on-line summary of the most essential data presented at the conference.

The CME Internet Symposium: AIDS 2020 Expert Review will feature a panel of HIV experts reviewing and discussing key presentations on antiretroviral therapy presented at AIDS 2020. The review and discussion will focus on HIV therapeutic options and developments, including: current treatment and management strategies, algorithms and recommendations, therapies in development, epidemiology, and diagnosis and clinical management of specific patient populations. This activity will enable participating health care providers caring for HIV-infected patients to become aware of and understand the data presented at this important conference and appropriately utilize those data to improve patient care. All online components of the program can be accessed at www.viraled.com.

This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at AIDS 2020 and it is not sanctioned by the organizers of AIDS 2020.

**These components are jointly provided by the Annenberg Center for Health Sciences and ViralEd, Inc., in collaboration with Postgraduate Institute for Medicine and supported by an independent educational grant from Janssen Therapeutics, Division of Janssen Products LP.  

Media: Internet

Back to Top

Target Audience

This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HIV infection.

Back to Top

Learning Objectives

After completing these activities, participants should be better able to:

  • Apply in a clinical setting the most current HIV prevention and treatment approaches and paradigms
  • Influence retention of patients on ARV therapy by addressing ARV side effects that can interfere with adherence to ARV regimens
  • Employ the rapid initiation of appropriate and effective antiretroviral therapy
  • Describe new antiretroviral agents in development and how they may be used in the treatment of people with HIV infection

Release Date: July 23, 2020

Expiration Date: July 23, 2021

Estimated time to complete the program: 30-45 minutes per module

Media: Internet

Back to Top


Faculty

José Arribas, MD
Senior Attending Physician, HIV Unit
Hospital de La Paz
Madrid, Spain

Marta Boffito, MD, PhD
St. Stephen's AIDS Trust and Imperial College
Chelsea and Westminster Hospital
London, United Kingdom

Ian Frank, MD
Professor of Medicine
Director, Clinical Therapeutics Program
Penn Center for AIDS Research
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

Graeme Moyle, MD, MB, BS
Associate Director of HIV Research
Chelsea & Westminster Hospital
London, United Kingdom 

Jürgen Rockstroh, MD
Professor of Medicine
Department of Medicine
University Hospital
Bonn, Germany

Paul Sax, MD
Clinical Director
Division of Infectious Diseases
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Renslow Sherer, MD
Professor of Medicine
Section of Infectious Diseases and Global Health
University of Chicago
Chicago, Illinois 

Back to Top

Joint Accreditation Statement

Jointly-Accredited-Provider-TM_1000x636 In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ViralEd, Inc. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Credit Designation

Hot Topics - Continuum of Care, Prevention and Cure Module:
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Studies in HIV Co-infection: Hepatitis, TB and COVID-19:
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Studies in Pregnancy and Treatment-Naive Patients Module: 
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Studies in Treatment-Experienced Module:
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Studies in Pharmacology Module:
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Adverse Effects and Co-morbidities Module: 
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Back to Top

 

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financialrelationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Jose Arribas, MD

  • Consulting Fees:Janssen, MSD,ViiV, Alexa, Teva

Marta Boffito, MD

  • Consulting Fees: Gilead, BMS, ViiV
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their agents (eg. speakers' bureaus): Gilead, Janssen, ViiV, BMS
  • Contracted Research: Gilead, Janssen, ViiV, BMS

Ian Frank, MD

  • Consulting Fees: Gilead, GSK
  • Contracted Research: Johnson & Johnson

Graeme Moyle, MD

  • Consulting Fees: Theratechnologies, Gilead, ViiV
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their agents (eg. speakers' bureaus): Theratechnologies, Gilead, ViiV
  • Contracted Research (institution only): Amgen, Merck, Gilead, ViiV

Jürgen Rockstroh, MD

  • Consulting Fees: Gilead, Merck, Janssen, Theratechnologies, ViiV
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their agents (eg. speakers' bureaus): AGilead, Merck, Janssen, ViiV

Paul Sax, MD

  • Consulting Fees: Gilead, GSK/ViiV, Janssen, Merck
  • Contracted Research: Gilead, GSK/ViiV, Merck
  • Other (Editorial Boards): Medscape, UpToDate, NEJM Journal Watch, Open Forum ID

Renslow Sherer, MD

  • Nothing to Disclose

The PIM planners and managers have nothing to disclose.


Back to Top

Request for Credit

If you wish to receive acknowledgment for completing this activity, please complete the evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID 15180. Upon registering and completing the activity evaluation, your certificate will be made available immediately.

Back to Top

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and donot necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Back to Top

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. 

Back to Top

Computer System Requirements

This program requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome). Certain educational activities may require additional software to view multimedia, presentation, or printable version of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player and Real Networks Real One Player. 

Back to Top

 

    PIM_small    VE logo 300px

 

 

This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs.

This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings.

 

 

Back to Top

 

     

Prepare to print

Share this page:

Get link code to this page     


Back to Top